Funding for this research was provided by:
Received: 13 September 2021
Accepted: 20 December 2021
First Online: 20 January 2022
: The ethical committee of the Kremlin-Bicêtre University Hospital (France) approved the study protocol, and written informed consent was obtained from each participant.
: Not applicable.
: CC, CB, CH, AG, and IJ declare that they have no competing interests. YD participated in advisory board for UCB Pharma, Jazz, Theranexus, Avadel, Idorsia, and Bioprojet, outside the submitted work.